menu
    • menu
    [{"orgOrder":0,"company":"Tr1X Bio","sponsor":"The Column Group","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Series A Financing","leadProduct":"TRX103","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Tr1X Bio","amount2":0.080000000000000002,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Tr1X Bio \/ The Column Group","highestDevelopmentStatusID":"5","companyTruncated":"Tr1X Bio \/ The Column Group"},{"orgOrder":0,"company":"Tr1X Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"TRX103","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Tr1X Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Tr1X Bio \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Tr1X Bio \/ Not Applicable"},{"orgOrder":0,"company":"Tr1X Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"TRX103","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Tr1X Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Tr1X Bio \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Tr1X Bio \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Tr1X Bio

    Menu

    Tr1X Bio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Tr1X Bio

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Tr1X Bio

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TRX103

                            Therapeutic Area : Gastroenterology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Tr1X Announces FDA Clearance of IND Application for TRX103 for Refractory Crohn’s Disease

                            Details : TRX103, a first-in-class Type 1 Treg cell therapy candidate, which is being evaluated for the treatment of patients with treatment-refractory crohn’s disease.

                            Brand Name : TRX103

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            August 07, 2024

                            Lead Product(s) : TRX103

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Tr1X Bio

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Tr1X Bio

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TRX103

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Tr1X Doses First Patient in GvHD Trial with TRX103, a Type 1 Treg Cell Therapy

                            Details : TRX103, a first-in-class Type 1 Treg cell therapy, is specifically designed for patients with autoimmune and inflammatory disorders, including those undergoing HSCT.

                            Brand Name : TRX103

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            July 10, 2024

                            Lead Product(s) : TRX103

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Tr1X Bio

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Tr1X Bio

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TRX103

                            Therapeutic Area : Immunology

                            Study Phase : IND Enabling

                            Sponsor : The Column Group

                            Deal Size : $75.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Tr1X Raises $75M for Universal CAR-Treg Therapies Development

                            Details : The net proceeds will be used to bring universal allogeneic regulatory T (Treg), including TRX103 and CAR-Treg cell therapies, TRX301, for autoimmune and inflammatory diseases.

                            Brand Name : TRX103

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            January 17, 2024

                            Lead Product(s) : TRX103

                            Therapeutic Area : Immunology

                            Highest Development Status : IND Enabling

                            Sponsor : The Column Group

                            Deal Size : $75.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth